


PRODUCT INFORMATION



AH 23848 (calcium salt)

Item No. 19023

CAS Registry No.: 81496-19-7
Formal Name: (4Z)-rel-7-[(1R,2R,5S)-5-([1,1'-biphenyl]-4-ylmethoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid, hemicalcium salt
MF: C₂₉H₃₄NO₅ • 1/2Ca
FW: 496.6
Purity: ≥90%
UV/Vis.: λ_{max}: 254 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AH 23848 (calcium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the AH 23848 (calcium salt) in the solvent of choice, which should be purged with an inert gas. AH 23848 (calcium salt) is soluble in the organic solvent DMSO at a concentration of approximately 5 mg/ml.

Description

Thromboxane (TXA₂) activates the T prostanoid (TP) receptor. Prostaglandin E₂ (PGE₂) activates four E prostanoid (EP) receptors, EP₁₋₄. AH 23848 is a dual antagonist of TP and EP₄ receptors.^{1,2} It originally was found to inhibit TXA₂-induced platelet aggregation (IC₅₀ = 0.26 μM) and the contraction of human bronchial smooth muscle induced by the TP agonist U-46619.^{1,3} AH 23848 was subsequently demonstrated to impair PGE₂-mediated relaxation of piglet saphenous vein by antagonizing the PGE₂ receptor EP₄.² By inhibiting EP₄, it likewise suppresses serum-induced cAMP generation, cyclin A synthesis, and the proliferation of fibroblasts, as well as reduces metastasis in a mouse model of metastatic breast cancer.^{4,5}

References

1. Brittain, R.T., Boutal, L., Carter, M.C., *et al.* AH23848: A thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A₂. *Circulation* **72**(6), 1208-1218 (1985).
2. Coleman, R.A., Grix, S.P., Head, S.A., *et al.* A novel inhibitory prostanoid receptor in piglet saphenous vein. *Prostaglandins* **47**(2), 151-168 (1994).
3. Coleman, R.A. and Sheldrick, R.L.G. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. *Br. J. Pharmacol.* **96**(3), 688-692 (1989).
4. Sanchez, T. and Moreno, J.J. Role of EP₁ and EP₄ PGE₂ subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation. *Am. J. Physiol. Cell Physiol.* **282**(2), C280-C288 (2002).
5. Ma, X., Kundu, N., Rifat, S., *et al.* Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. *Cancer Res.* **66**(6), 2923-2927 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/08/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM